Development of an intranasal formulation containing indomethacin and xylometazoline for rhinosinusitis treatment.

Kar M., Ince I., Yildirim C., Burukoğlu Dönmez D., Karasulu Y., Cingi C.

European review for medical and pharmacological sciences, vol.26, no.2 Suppl, pp.65-71, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 2 Suppl
  • Publication Date: 2022
  • Doi Number: 10.26355/eurrev_202212_30486
  • Journal Name: European review for medical and pharmacological sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Page Numbers: pp.65-71
  • Keywords: Xylometazoline, Indomethacin, Intranasal Formulation, PERMEATION
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

OBJECTIVE: Use of the nasal route of drug administration dates back many years and is used both to achieve topical treatments and to allow systemic absorption. The objective was to develop a formulation with novel features which enhance prolonged contact with the nasal and sinusal lining, since this should increase any therapeutic benefit. The anti-inflammatory drug selected was indomethacin, which was combined with xylometazoline, an effective nasal decongestant agent.